RM LAW Announces Class Action Lawsuit Against Ocular Therapeutix, Inc.

BERWYN, Pa., July 12, 2017 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Ocular Therapeutix, Inc. (NASDAQ: OCUL) ("Ocular" or the "Company") securities between May 5, 2017 and July 6, 2017, inclusive (the "Class Period").

Ocular shareholders may, no later than September 5, 2017, move the Court for appointment as a lead plaintiff of the Class.  If you purchased shares of Ocular and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.

Ocular, a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery.

On July 6, 2017, near the close of trading, the investor website Seeking Alpha published an article entitled "Ocular: A Poke In The Eye," reporting that Ocular is on "the brink of collapse" and that they may be "misleading investors" about ongoing manufacturing issues and the Company's communications with the FDA about those issues.

On this news, Ocular's stock has fallen more than 30% to close at $7.12 on July 7, 2017, causing tens of millions in losses to shareholders.

If you are a member of the class, you may, no later than September 5, 2017, request that the Court appoint you as lead plaintiff of the class. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  You may retain RM LAW, P.C. or other counsel of your choice, to serve as your counsel in this action.

For more information regarding this, please contact RM LAW, P.C.  (Richard A. Maniskas, Esquire) toll-free at (844) 291-9299 or by email at rm@maniskas.com or click here. For more information about class action cases in general or to learn more about RM LAW, P.C. please visit our website: www.maniskas.com.

RM LAW, P.C. is a national shareholder litigation firm.  RM LAW, P.C. is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

CONTACT: RM LAW, P.C.
Richard A. Maniskas, Esquire
1055 Westlakes Dr., Ste. 3112
Berwyn, PA 19312
484-324-6800
844-291-9299
rm@maniskas.com

View original content with multimedia:http://www.prnewswire.com/news-releases/rm-law-announces-class-action-lawsuit-against-ocular-therapeutix-inc-300487373.html

SOURCE RM LAW, P.C.